News
published at: 11.07.2024
Leukemia research: Important genetic switchpoint for early hematopoiesis decoded
published at: 11.07.2024
DKFZ/NCT/DKTK-MASTER study: Molecular analysis supports therapy decisions in rare cancers
published at: 11.07.2024
Comprehensive molecular analysis in cancer of unknown primary can improve cancer therapy
published at: 11.07.2024
Global guidelines to improve the quality of microscopy images in scientific publications
published at: 05.03.2026
RELAX study from Dresden: Innovative combination therapy shows promising efficacy in aggressive leukemia
Acute myeloid leukemia (AML) is a particularly aggressive form of blood cancer that usually progresses rapidly if swift and intensive treatment is not applied. Although the disease can often be contained by chemotherapy (remission), it returns in many patients. A permanent cure is often only possible with a stem cell transplant - provided that the leukemia can be sufficiently contained beforehand. A new Germany-wide study led by the Dresden University Medicine has shown that the combination of intensive chemotherapy and the substance venetoclax can significantly improve the success rate of treatment of aggressive acute leukemia. This has been confirmed by the results of RELAX, with remission in 75% of the cases compared to the past attempts yielding an only 40 percent remission rate. The study was published today, March 4, in the renowned journal The Lancet Haematology.
published at: 29.04.2026
MDS Therapy: Dresden Team Demonstrates Tasquinimod’s Potential for Improved Blood Formation and Treatment of Bone Damage
Researchers at Dresden University Hospital may have discovered a new therapeutic approach for treating myelodysplastic syndromes (MDS). In a recent study, the team headed by Prof. Manja Wobus and Dr. Katja Sockel demonstrated that the anti-inflammatory drug tasquinimod improves blood formation—which is impaired in MDS—and reduces bone damage in preclinical models. Their findings address two central and closely related clinical issues associated with MDS. The corresponding study on the preclinical efficacy of tasquinimod in myelodysplastic syndromes was recently published in the journal “HemaSphere,” a specialist journal for hematology.
